An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak wątrobowokomórkowy.
- •Potwierdzony histologicznie rak dróg żółciowych w wątrobie.
- •Pacjent przeszedł standardowe badania diagnostyczne.
- •Posiadanie próbki krwi pobranej przed rozpoczęciem leczenia.
✗ Disqualifies
- •Brak zgody na udział w badaniu.
- •Jednoczesny rak wątrobowokomórkowy i rak dróg żółciowych.
- •Inny rodzaj pierwotnego raka wątroby niż wymienione.
- •Wtórny rak wątroby (przerzuty).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
City of Hope Medical Center
Duarte, United States
Graduate School of Medical Sciences, Kyushu University
Fukuoka, Japan
Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan
Hokkaido University Graduate School of Medicine
Sapporo, Japan
Tokushima University
Tokushima, Japan
Trial contact
Ajay Goel, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.